BLUE GENES NEWS

All News

All News Press Releases PGX Center
New York Labor Health Care Alliance Endorses Blue Genes Lab to Stop Unsafe and Ineffective Drugs Before They're Filled for 79 Unions and 150,000 Members and Dependents

New York Labor Health Care Alliance Endorses Blue Genes Lab to Stop Unsafe and Ineffective Drugs Before They're Filled for 79 Unions and 150,000 Members and Dependents

October 20, 2026 • Press Releases

Blue Genes Lab, a leading pharmacogenetics (PGx) provider with a groundbreaking approach to using genetic data to protect patients and reduce costs for payers at the moment it matters, today announced that it has been endorsed by the New York Labor Health Care Alliance (NYLHCA) for use by its 79 member unions representing 150,000 members and dependents.
Blue Genes CEO Nick Glimcher Featured in TopDoctor Magazine

Blue Genes CEO Nick Glimcher Featured in TopDoctor Magazine

October 14, 2026 • Press Releases

TopDoctor Magazine sat down with Blue Genes CEO Nick Glimcher to talk about why so many genetic results never make it from the chart to the prescription, and what it takes to change that.

 TRU-1 By Blue Genes Launches to Advance Precision Health Through Smarter Genetic Insights

TRU-1 By Blue Genes Launches to Advance Precision Health Through Smarter Genetic Insights

May 21, 2026 • Press Releases

TRU-1 by Blue Genes has officially launched, introducing a new approach to precision wellness through genetic insight. The platform is designed to help provide additional visibility into how individuals may respond differently to wellness strategies, supplements, and GLP-1 related programs based on their genetics.

Latest News

Blue Genes Successfully Completes SOC 2 Audit

Blue Genes Successfully Completes SOC 2 Audit

January 19, 2026 • Press Releases

Phoenix, AZ, January 16, 2026 — Blue Genes (https://bluegeneslab.com), a personalized medicine company focused on pharmacogenetic (PGx) testing and genetic insights to support safer, more effective medication decisions, today announced the successful completion of its SOC 2 Type II examination as of January 16, 2025.
Blue Genes Lab Expands Genetic Panel to Include Three New GLP-1–Related Genes

Blue Genes Lab Expands Genetic Panel to Include Three New GLP-1–Related Genes

September 08, 2025 • Press Releases

SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Blue Genes Lab, a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that influence GLP‑1 (glucagon‑like peptide‑1) biology. The expanded panel aims to improve personalized treatment strategies for metabolic conditions such as type 2 diabetes, obesity, and related cardiometabolic risks by providing clinicians and patients with a deeper genetic view of pathways that regulate GLP‑1 signaling, secretion, and response.
Blue Genes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience

Blue Genes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience

June 19, 2025 • Press Releases

SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- Blue Genes, a leading pharmacogenetics (PGX) solution, and Levrx Technology, a digital pharmacy engagement platform, have announced a strategic partnership. Together they aim to accelerate the adoption of personalized prescribing by seamlessly integrating genetic testing insights into pharmacy benefit systems.
Blue Genes Partners with Level Care to Revolutionize Medication Management for Union Members

Blue Genes Partners with Level Care to Revolutionize Medication Management for Union Members

April 21, 2025 • Press Releases

SCOTTSDALE, AZ – Blue Genes, a pioneering technology company specializing in precision medicine, today announced a strategic partnership with Level Care, the healthcare division of the carpenters union. This collaboration will provide Level Care members with access to Blue Genes' cutting-edge pharmacogenomic (PGX) testing, ensuring safer and more effective medication management.
Minimizing the Guessing Game in Pain Management

Minimizing the Guessing Game in Pain Management

May 08, 2024 • PGX Center

A New Study Brings Pharmacogenetics to Postoperative Care Patients preparing to undergo surgery face many unknowns. Will the surgery improve their quality of life? How long will they take to recover? Many are concerned about the pain and discomfort surrounding the surgery. What they may not be considering is how their body will respond to pain medication(s) prescribed during and after surgery.
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care

A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care

May 08, 2024 • PGX Center

Adverse drug reactions (ADRs) are a significant public health concern and a leading cause of hospitalization; they are estimated to be the fourth leading cause of death and increasing healthcare costs worldwide. Carrying a genetic variant could alter the efficacy and increase the risk of ADRs associated with a drug in a target population for commonly prescribed drugs.
© 2026 Blue Genes - Pharmacogenetics (PGX) Testing Kits | Privacy Policy | Terms of Use | SMS Help